Intellia Therapeutics reported third-quarter 2026 results and progress across its gene-editing pipeline, with the focus on preparing its hereditary angioedema treatment candidate, lonvo-z, for a possible U.S. launch in 2027. The FDA has set a March 10, 2027 decision date for the treatment, which would be the first in vivo CRISPR-based therapy if approved.
The company also reported progress in Phase 3 trials of nex-z for transthyretin amyloidosis and said its cash resources, supplemented by a new loan facility, are expected to support operations into 2028 and beyond lonvo-z’s anticipated launch.
Key details
- Lonvo-z review and launch preparation: The FDA accepted Intellia’s application for lonvo-z in September and granted it priority review, with a target decision date of March 10, 2027. The agency is not currently planning an advisory committee meeting for the application.
- Potential one-time HAE treatment: Lonvo-z is designed to be given once, in an outpatient setting, and to edit a gene involved in producing kallikrein. Intellia says the approach is intended to reduce kallikrein and bradykinin levels and eliminate HAE attacks and the need for lifelong treatment. Those are intended effects, not established outcomes.
- Commercial readiness: Intellia said it has completed deployment of its field organization and increased engagement with HAE treatment centers and payers. It is preparing for a planned commercial launch in the first quarter of 2027, subject to approval.
- Nex-z trial progress: Enrollment is complete in MAGNITUDE-2, a Phase 3 trial of nex-z in hereditary ATTR amyloidosis with polyneuropathy. Intellia said enrollment exceeded its target of 60 patients. Enrollment also advanced in the MAGNITUDE Phase 3 trial in ATTR amyloidosis with cardiomyopathy.
- Genotyping in ongoing trials: During the quarter, Intellia began providing investigators with HLA genotyping results for patients enrolled in, or entering screening for, its nex-z Phase 3 trials.
- New financing: In September, Intellia entered a senior secured term-loan facility with healthcare investor OrbiMed for up to $400 million. The company describes the financing as non-dilutive and says it adds financial and operational flexibility. The announced maximum is a facility size, not a statement that the full amount has been drawn.
- Cash runway: Intellia expects its existing cash resources to fund operations at least into 2028 and well beyond lonvo-z’s anticipated commercial launch. The announcement does not provide specific third-quarter revenue, net-loss or cash-balance figures in the material provided here.
- Medical leadership: In October, Jing L. Marantz was appointed executive vice president and chief medical officer. She is leading the company’s translational, development, regulatory and medical-affairs functions.
- Upcoming lonvo-z update: Intellia plans an investor webcast on November 12, alongside presentations the following week at the American College of Allergy, Asthma & Immunology meeting. The company said these will include new patient perspectives and Phase 1/2 durability data for lonvo-z.
Plain-English implications: Intellia is moving lonvo-z toward a regulatory decision while building the commercial organization needed for a potential launch. The loan facility provides another source of financing without issuing shares, but it is secured debt. Meanwhile, nex-z remains in Phase 3 development, with enrollment complete in one trial and advancing in another.